A clinical trial of repotrectinib in patients with advanced solid tumors harboring NTRK, ALK, or ROS1 rearrangements (TRIDENT-1, NCT03093116) are currently being conducted, of which the interim data showed evident antitumor activity of repotrectinib in patients harboring NTRK fusion-positive cancers both with and without previous NTRK-TKI treatment (98). This evidence concerns the gene ROS1 and cancer.